As of 2024-10-07, the Intrinsic Value of Bristol-Myers Squibb Co (BMY) is
61.27 USD. This Bmy valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 53.96 USD, the upside of Bristol-Myers Squibb Co is
13.50%.
The range of the Intrinsic Value is 46.70 - 84.53 USD
61.27 USD
Intrinsic Value
Bmy Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
46.70 - 84.53 |
61.27 |
13.5% |
| DCF (Growth 10y) |
60.89 - 103.80 |
77.47 |
43.6% |
| DCF (EBITDA 5y) |
30.15 - 56.16 |
42.51 |
-21.2% |
| DCF (EBITDA 10y) |
46.15 - 76.87 |
60.42 |
12.0% |
| Fair Value |
-16.13 - -16.13 |
-16.13 |
-129.90% |
| P/E |
(63.49) - 108.42 |
(10.40) |
-119.3% |
| EV/EBITDA |
58.24 - 169.03 |
107.69 |
99.6% |
| EPV |
143.93 - 185.40 |
164.67 |
205.2% |
| DDM - Stable |
(30.14) - (61.91) |
(46.03) |
-185.3% |
| DDM - Multi |
41.41 - 67.37 |
51.40 |
-4.7% |
Bmy Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
109,398.51 |
| Beta |
0.24 |
| Outstanding shares (mil) |
2,027.40 |
| Enterprise Value (mil) |
155,494.50 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.09% |
| Cost of Debt |
4.25% |
| WACC |
6.11% |